NaviFUS and Bracco Sign Cooperation Agreement for Precision FUS Treatment
NaviFUS (6872) and Bracco, the world’s leading brand of ultrasound imaging agents, officially signed a cooperation agreement recently. The collaboration will greatly assist the NaviFUS® System’s treatment in opening the blood-brain barrier (BBB). As a technology platform, the NaviFUS® System will be used in multiple pilot and pivotal clinical trials for treatment of various brain cancers or neurological diseases this year.
General Manager Arthur Lung of NaviFUS stated Mr. Fulvio Renoldi Bracco, CEO of Bracco Group, personally visited NaviFUS before Christmas last year. Besides leaving a positive impression of NaviFUS’ professionalism and potential, a mutual understanding of both companies’ product synergies and a shared vision of the focused ultrasound treatment market were major reasons leading to a successful cooperation agreement. A pivotal stage clinical trial is expected to launch at National Taiwan University and Chang Gung Memorial Hospital in the second half of the year, and the collaboration aims to develop an enhanced product that can improve treatment of recurrent glioblastoma patients. NaviFUS strives to bring its non-invasive and precise ultrasound treatment to market soon in order to give brain tumor patients new hope and a less burdensome experience.
View source version
https://www.taiwan-healthcare.org/zh/news-detail?id=0rud9zirj4r8pvkf